Drugging cell cycle kinases in cancer therapy.
Blagden S. and de Bono J., (2005), Curr Drug Targets, 6, 325 - 335
Docetaxel in the management of ovarian cancer.
Blagden SP. and Kaye SB., (2005), Expert Rev Anticancer Ther, 5, 203 - 214
A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours.
Steele N. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 200S - 200S
Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies.
Pacey S. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 205S - 205S
Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on Day 1 (T and C) and Day 8 (T) every three weeks in patients (pts) with advanced solid tumors
Blagden S. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 226S - 226S
Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors.
Blagden S. et al, (2005), CLINICAL CANCER RESEARCH, 11, 9119S - 9119S
Performance status score: do patients and their oncologists agree?
Blagden SP. et al, (2003), Br J Cancer, 89, 1022 - 1027
Polar expeditions--provisioning the centrosome for mitosis.
Blagden SP. and Glover DM., (2003), Nat Cell Biol, 5, 505 - 511
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Corrie P. et al, (2002), Br J Cancer, 87, 716 - 719
The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours.
Blagden SP. et al, (2002), Br J Cancer, 86, 26 - 30
Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics.
Lo SK. et al, (1999), Lancet, 353, 2038 - 2039